瑞舒伐他汀强化治疗对急性ST段抬高型心肌梗死患者PCI手术预后的影响

目的:探讨瑞舒伐他汀强化治疗对急性ST段抬高型心肌梗死(STEMI)患者PCI术预后的影响。方法:选择2013年6月-2015年6月我院收治的STEMI患者90例,随机分为研究组与对照组,每组各45例。研究组患者PCI术前及术后均给予瑞舒伐他汀强化治疗,对照组仅在术后给予瑞舒伐他汀治疗。观察并比较两组患者术中慢血流及无复流的发生率,TNI、CK-MB、NT-pro BNP及hs-CRP水平变化,以及左室舒张末期内径、左心房内径、左室射血分数、室间隔厚度。结果:研究组术中慢血流及无复流的发生率显著低于对照组(P0.05);两组患者治疗后TNI、CK-MB、NT-pro BNP、hs-CRP水平均低于治疗前,且研究组低于对照组,差异具有统计学意义(P0.05);两组治疗后左室舒张末期内径、左心房内径、左室射血分数、室间隔厚度比较,差异无统计学意义(P0.05)。结论:瑞舒伐他汀强化治疗可以有效降低STEMI患者心肌坏死及炎症反应的发生率,改善心室重构,值得临床推广应用。

Effects of Rosuvastatin Intensive Treatment on Prognosis of PCI for Patients with Acute ST Segment Elevation Myocardial Infarction

Objective:To investigate the effect of rosuvastatin fortified treatment of patients with acute ST segment elevation myocardial infarction (STEMI) who had taken the PCI.Methods:90 patients with STEMI who were treated in our hospital from June 2013 to June 2015 were selected and randomly divided into the study group and the control group, with 45 cases in each group. The patients in the study group were treated with rosuvastatin before and after the surgery, while the patients in the control group were treated with rosuvastatin after the surgery.Results:After treatment, the blood flow in the two groups were significantly lower than before, and the study group was lower than that of the control group with statistically significant differences (P<0.05); The levels of TNI, CK-MB, NT-proBNP and hs-CRP in the two groups after the treatment were lower than before, and the study group was lower than that of the control group with statistically significant differences (P <0.05); There was no statistically significant difference about the LVEDD, LAD, LVEF and IVST in the two groups after the treatment (P>0.05).Conclusion:The rosuvastatin have remarkable effect on the treatment of patients with STEMI who had taken the PCI surgery, which can reduce the myocardial necrosis and inflammation, so as to improve the ventricular remodeling and prognosis.